Cumberland Pharmaceuticals Inc (CPIX) Stock Analysis and Metrics

Cumberland Pharmaceuticals

NASDAQ: CPIX

$6.61 ▼ -0.38 (-5.37%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap99.04 Mn

P/E-13.68

P/S2.36

Div. Yield0.00

Total Debt (Qtr)5.24 Mn

Revenue Growth (1y) (Qtr)-22.04

Add ratio to table…

About

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition development and commercialization of branded prescription pharmaceuticals. The company is dedicated to its mission of working together to provide unique products that improve the quality of patient care. Its primary target markets are hospital acute care gastroenterology and oncology. These specialties are characterized by relatively concentrated prescriber bases that the company believes can be served effectively by small targeted sales forces. Cumberland promotes its approved products through its hospital field and oncology sales divisions in the United States and has built a network of established international partners with the regulatory and commercial capabilities to register and provide its medicines to patients in their countries.

Cumberland Pharmaceuticals Inc. generates revenue primarily from the sale of its FDA approved branded products which include Acetadote ® injection for the treatment of acetaminophen poisoning Caldolor ® injection for the treatment of pain and fever Kristalose ® oral solution a prescription laxative for the treatment of constipation Sancuso ® transdermal for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment Vaprisol ® injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia Vibativ ® injection for the treatment of certain serious bacterial infections including hospital acquired and ventilator associated bacterial pneumonia as well as complicated skin and skin structure infections and Talicia ® oral capsule for the treatment of H pylori infection. In addition to product sales the company receives revenue from milestone payments royalties and co promotion arrangements such as its joint commercialization of Talicia with RedHill Biopharma Ltd. International sales are generated through partners like Tabuk Pharmaceutical Manufacturing Company which has exclusive rights to distribute Vibativ in Saudi Arabia and Jordan PiSA Farmaceutica which holds exclusive supply and distribution rights for Caldolor in Mexico and distribution agreements with Vizient Inc. and Premier Inc. that make its products available to a broad base of health care providers. The company also earns other revenue from its subsidiary Cumberland Emerging Technologies which supports early stage product development.

Cumberland Pharmaceuticals Inc. operates in a highly competitive specialty pharmaceutical environment where it contends with other branded products generic alternatives and over the counter therapies. For Kristalose the primary competitors include prescription drugs such as Amitiza ® Movantik ® Linzess ® and Vibrant ® as well as numerous generic lactulose products and over the counter options like MiraLax ®. Vibativ faces competition from other antibiotics used to treat hospital acquired and ventilator associated bacterial pneumonia and complicated skin infections. Sancuso competes with other antiemetic agents used to prevent chemotherapy induced nausea and vomiting. The company’s competitive advantages stem from its focus on concentrated prescriber bases in hospital acute care gastroenterology and oncology its ability to deploy small targeted sales forces its ownership of worldwide rights for most of its brands except Sancuso its established international partnership network and its pipeline of investigational product candidates. Notably Cumberland is advancing ifetroban a novel oral therapy through Phase II studies in Duchenne muscular dystrophy systemic sclerosis and idiopathic pulmonary fibrosis which could provide future growth drivers if successful.

Cumberland Pharmaceuticals Inc. serves hospitals acute care providers gastroenterology and oncology specialists and other health care institutions that prescribe its products. Specific customer relationships include group purchasing organizations such as Vizient Inc. which provides access to more than sixty five percent of acute care providers including ninety seven percent of academic medical centers and Premier Inc. which unites an alliance of approximately four thousand three hundred fifty hospitals and three hundred twenty five thousand other providers and organizations. The company also works with international distribution partners like Tabuk Pharmaceutical Manufacturing Company which has exclusive rights to distribute Vibativ in Saudi Arabia and Jordan PiSA Farmaceutica which holds exclusive supply and distribution rights for Caldolor in Mexico and RedHill Biopharma Ltd. with which it co promotes Talicia in the United States. Additionally Cumberland supplies its products through wholesalers and pharmacies that deliver the medicines to end users such as patients in hospital outpatient clinics and retail pharmacy settings.

Investment Thesis

▲ Bull case

Cumberland Pharmaceuticals Inc. is positioned for transformative growth through its strategic transaction with Apotex, which will unlock $100 million in cash proceeds that can be redeployed into high-potential clinical programs, particularly the ifetroban pipeline targeting Duchenne muscular dystrophy-associated cardiomyopathy, where the company has already demonstrated clinically meaningful efficacy with a 5.4% improvement in left ventricular ejection fraction versus natural history controls and secured FDA Fast Track designation, creating a clear regulatory pathway to approval that addresses a fatal underserved condition with no current disease-modifying therapies, thereby establishing a potential multi-hundred-million-dollar revenue opportunity upon commercialization that the market has not fully priced into the stock given the current focus on near-term branded product performance.
The company's international expansion of Vibativ into China through its partnership with SciClone Pharmaceuticals represents a significant and underappreciated catalyst, as the world's second-largest pharmaceutical market provides access to a rapidly growing demand for advanced anti-infectives amid rising antimicrobial resistance, with Vibativ's dual mechanism of action offering differentiated efficacy against multidrug-resistant Gram-positive pathogens, and the recent launch in Saudi Arabia and regulatory approval in Mexico further de-risking the international rollout, suggesting that Vibativ could evolve into a global franchise with sustained double-digit growth potential beyond the U.S. market, especially as the company has already secured a $3 million milestone payment from the China approval and is positioned to receive ongoing royalties that could meaningfully contribute to top-line expansion in 2026 and beyond.
Talicia, the company's newest FDA-approved brand for Helicobacter pylori infection, is gaining strong traction as a first-line therapy per American College of Gastroenterology guidelines, with over 90% eradication rates and minimal antibiotic resistance, and its co-commercialization structure with RedHill Biopharma allows Cumberland to leverage its established field sales force while sharing net revenues equally, creating a low-capital-intensity growth engine; the product's recent integration into major formularies such as Humana's Medicare Part D covering eight million lives, combined with published data supporting a convenient three-times-daily dosing regimen that improves adherence, indicates that Talicia is well-positioned to capture increasing share in the H. pylori treatment market, which affects nearly half of the global population and remains under-penetrated by branded therapies due to historical reliance on multi-pill regimens with lower compliance.
Cumberland's development of ifetroban for systemic sclerosis and idiopathic pulmonary fibrosis represents a valuable optionality that is not being adequately valued by the market, as the drug has demonstrated a strong safety profile across over 1,400 subjects in clinical trials with no serious drug-related adverse events, and the ongoing Phase II studies in these indications are supported by compelling mechanistic rationale—targeting thromboxane A2 receptor-mediated fibrosis and inflammation—with interim safety data already showing no new signals in the pulmonary fibrosis program, suggesting that success in either indication could unlock additional orphan drug pathways and broaden the therapeutic applicability of ifetroban beyond Duchenne muscular dystrophy, thereby creating multiple shots on goal for near-term clinical milestones and potential FDA interactions that could catalyze re-rating of the stock as a diversified clinical-stage biopharma opportunity.
The company's improved financial discipline is evident in its strengthened balance sheet, with over $11 million in cash and cash equivalents as of Q1 2026, a reduced credit facility balance of $5.2 million, and shareholder equity rising to $21.6 million, reflecting successful deleveraging from prior acquisitions and disciplined capital allocation; this financial flexibility, combined with the impending $100 million proceeds from the Apotex transaction, positions Cumberland to fund its clinical pipeline through critical inflection points without relying on dilutive financing, thereby reducing near-term financing risk and enabling a sharper focus on value-creating R&D milestones that could drive long-term shareholder returns.

Cumberland Pharmaceuticals Inc. is positioned for transformative growth through its strategic transaction with Apotex, which will unlock $100 million in cash proceeds that can be redeployed into high-potential clinical programs, particularly the ifetroban pipeline targeting Duchenne muscular dystrophy-associated cardiomyopathy, where the company has already demonstrated clinically meaningful efficacy with a 5.4% improvement in left ventricular ejection fraction versus natural history controls and secured FDA Fast Track designation, creating a clear regulatory pathway to approval that addresses a fatal underserved condition with no current disease-modifying therapies, thereby establishing a potential multi-hundred-million-dollar revenue opportunity upon commercialization that the market has not fully priced into the stock given the current focus on near-term branded product performance.
The company's international expansion of Vibativ into China through its partnership with SciClone Pharmaceuticals represents a significant and underappreciated catalyst, as the world's second-largest pharmaceutical market provides access to a rapidly growing demand for advanced anti-infectives amid rising antimicrobial resistance, with Vibativ's dual mechanism of action offering differentiated efficacy against multidrug-resistant Gram-positive pathogens, and the recent launch in Saudi Arabia and regulatory approval in Mexico further de-risking the international rollout, suggesting that Vibativ could evolve into a global franchise with sustained double-digit growth potential beyond the U.S. market, especially as the company has already secured a $3 million milestone payment from the China approval and is positioned to receive ongoing royalties that could meaningfully contribute to top-line expansion in 2026 and beyond.
Talicia, the company's newest FDA-approved brand for Helicobacter pylori infection, is gaining strong traction as a first-line therapy per American College of Gastroenterology guidelines, with over 90% eradication rates and minimal antibiotic resistance, and its co-commercialization structure with RedHill Biopharma allows Cumberland to leverage its established field sales force while sharing net revenues equally, creating a low-capital-intensity growth engine; the product's recent integration into major formularies such as Humana's Medicare Part D covering eight million lives, combined with published data supporting a convenient three-times-daily dosing regimen that improves adherence, indicates that Talicia is well-positioned to capture increasing share in the H. pylori treatment market, which affects nearly half of the global population and remains under-penetrated by branded therapies due to historical reliance on multi-pill regimens with lower compliance.
Cumberland's development of ifetroban for systemic sclerosis and idiopathic pulmonary fibrosis represents a valuable optionality that is not being adequately valued by the market, as the drug has demonstrated a strong safety profile across over 1,400 subjects in clinical trials with no serious drug-related adverse events, and the ongoing Phase II studies in these indications are supported by compelling mechanistic rationale—targeting thromboxane A2 receptor-mediated fibrosis and inflammation—with interim safety data already showing no new signals in the pulmonary fibrosis program, suggesting that success in either indication could unlock additional orphan drug pathways and broaden the therapeutic applicability of ifetroban beyond Duchenne muscular dystrophy, thereby creating multiple shots on goal for near-term clinical milestones and potential FDA interactions that could catalyze re-rating of the stock as a diversified clinical-stage biopharma opportunity.
The company's improved financial discipline is evident in its strengthened balance sheet, with over $11 million in cash and cash equivalents as of Q1 2026, a reduced credit facility balance of $5.2 million, and shareholder equity rising to $21.6 million, reflecting successful deleveraging from prior acquisitions and disciplined capital allocation; this financial flexibility, combined with the impending $100 million proceeds from the Apotex transaction, positions Cumberland to fund its clinical pipeline through critical inflection points without relying on dilutive financing, thereby reducing near-term financing risk and enabling a sharper focus on value-creating R&D milestones that could drive long-term shareholder returns.

▼ Bear case

Cumberland Pharmaceuticals Inc. faces significant near-term revenue headwinds as its core branded portfolio shows signs of maturation, with Kristalose experiencing increased generic substitution and pricing pressure that management acknowledged but did not fully quantify, and while Sancuso continues to perform well, its growth is constrained by the competitive landscape in chemotherapy-induced nausea prevention where newer entrants and evolving treatment paradigms could limit long-term adoption, raising concerns that the company's reliance on a few key products may not sustain the double-digit growth trajectory it has historically achieved, especially as the Vibativ milestone payments from China are non-recurring and the international launches in Saudi Arabia and Mexico are still in early stages with unclear scalability.
The strategic transaction with Apotex, while providing a substantial cash infusion, carries execution and integration risks that were not adequately addressed in the communications, including the potential for delayed shareholder approval, unforeseen closing conditions, or post-closing disputes over the valuation of the branded portfolio, and more critically, the transaction will result in Cumberland relinquishing control over its commercial infrastructure and field sales team—the very assets that have driven the success of products like Talicia and Sancuso—thereby creating uncertainty about how effectively the company will be able to promote its pipeline candidates or future commercialized products without its established sales force, which management framed as a strategic sharpening but did not substantiate with a clear plan for maintaining market access or promotional capabilities post-transaction.
The ifetroban development program, despite promising signals in Duchenne muscular dystrophy, remains subject to significant clinical and regulatory uncertainty, as the Phase II trial was small (n=41) and the observed 5.4% improvement in left ventricular ejection fraction, while statistically significant versus natural history controls, may not be deemed clinically meaningful by the FDA for approval, especially given the lack of a placebo-controlled difference in the primary endpoint that met conventional thresholds for significance, and the company's reliance on propensity-matched historical controls introduces potential bias that could undermine the robustness of the efficacy data, thereby increasing the risk of a complete clinical hold or request for additional trials that would delay approval and burn through cash reserves.
Talicia's long-term commercial potential is exposed to competitive threats from emerging Helicobacter pylori therapies and the possibility of declining infection rates due to improved sanitation and antibiotic stewardship, yet management did not discuss any lifecycle management strategies or secondary indications for the product, nor did they address the dependency on RedHill Biopharma for the joint venture's success, particularly given RedHill's own financial volatility and history of losses in its continuing operations, which could jeopardize the stability of the Talicia Holdings partnership and Cumberland's ability to derive consistent value from the asset, especially if RedHill fails to meet its funding commitments or prioritizes other pipeline programs over Talicia commercialization.
Cumberland's financial improvement, while real, is largely driven by non-recurring items such as the $3 million milestone payment from China and cost savings from deleveraging, rather than organic profitability, as evidenced by the continued GAAP net loss of $3.3 million in Q1 2026 and an adjusted loss of $1.9 million, indicating that the company is not yet generating sustainable earnings from operations, and with operating expenses remaining high at $12.3 million for the quarter, there is little room for error if revenue growth from Talicia or international Vibativ sales fails to accelerate, raising the specter of renewed cash burn and potential need for dilutive financing despite the upcoming Apotex proceeds, which may be viewed by investors as a one-time event rather than a sign of enduring financial health.

Cumberland Pharmaceuticals Inc. faces significant near-term revenue headwinds as its core branded portfolio shows signs of maturation, with Kristalose experiencing increased generic substitution and pricing pressure that management acknowledged but did not fully quantify, and while Sancuso continues to perform well, its growth is constrained by the competitive landscape in chemotherapy-induced nausea prevention where newer entrants and evolving treatment paradigms could limit long-term adoption, raising concerns that the company's reliance on a few key products may not sustain the double-digit growth trajectory it has historically achieved, especially as the Vibativ milestone payments from China are non-recurring and the international launches in Saudi Arabia and Mexico are still in early stages with unclear scalability.
The strategic transaction with Apotex, while providing a substantial cash infusion, carries execution and integration risks that were not adequately addressed in the communications, including the potential for delayed shareholder approval, unforeseen closing conditions, or post-closing disputes over the valuation of the branded portfolio, and more critically, the transaction will result in Cumberland relinquishing control over its commercial infrastructure and field sales team—the very assets that have driven the success of products like Talicia and Sancuso—thereby creating uncertainty about how effectively the company will be able to promote its pipeline candidates or future commercialized products without its established sales force, which management framed as a strategic sharpening but did not substantiate with a clear plan for maintaining market access or promotional capabilities post-transaction.
The ifetroban development program, despite promising signals in Duchenne muscular dystrophy, remains subject to significant clinical and regulatory uncertainty, as the Phase II trial was small (n=41) and the observed 5.4% improvement in left ventricular ejection fraction, while statistically significant versus natural history controls, may not be deemed clinically meaningful by the FDA for approval, especially given the lack of a placebo-controlled difference in the primary endpoint that met conventional thresholds for significance, and the company's reliance on propensity-matched historical controls introduces potential bias that could undermine the robustness of the efficacy data, thereby increasing the risk of a complete clinical hold or request for additional trials that would delay approval and burn through cash reserves.
Talicia's long-term commercial potential is exposed to competitive threats from emerging Helicobacter pylori therapies and the possibility of declining infection rates due to improved sanitation and antibiotic stewardship, yet management did not discuss any lifecycle management strategies or secondary indications for the product, nor did they address the dependency on RedHill Biopharma for the joint venture's success, particularly given RedHill's own financial volatility and history of losses in its continuing operations, which could jeopardize the stability of the Talicia Holdings partnership and Cumberland's ability to derive consistent value from the asset, especially if RedHill fails to meet its funding commitments or prioritizes other pipeline programs over Talicia commercialization.
Cumberland's financial improvement, while real, is largely driven by non-recurring items such as the $3 million milestone payment from China and cost savings from deleveraging, rather than organic profitability, as evidenced by the continued GAAP net loss of $3.3 million in Q1 2026 and an adjusted loss of $1.9 million, indicating that the company is not yet generating sustainable earnings from operations, and with operating expenses remaining high at $12.3 million for the quarter, there is little room for error if revenue growth from Talicia or international Vibativ sales fails to accelerate, raising the specter of renewed cash burn and potential need for dilutive financing despite the upcoming Apotex proceeds, which may be viewed by investors as a one-time event rather than a sign of enduring financial health.

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password